Merck agrees to acquire Rapid Micro Biosystems for US$ 0.75 per share in cash
- Merck KGaA has signed a definitive agreement to acquire Rapid Micro Biosystems for US$ 0.75 per share in cash.
- Closing is expected in December 2026, subject to customary conditions, including the tender of at least a majority of outstanding voting shares.
- The acquisition would add the Growth Direct automated microbial testing platform to its pharmaceutical quality-control portfolio, advancing its integrated workflow strategy.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160957PRIMZONEFULLFEED9878430) on November 16, 2026, and is solely responsible for the information contained therein.